Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study

Blood Advances - Tập 7 - Trang 4462-4474 - 2023
Federica R. Achini-Gutzwiller1,2,3, Marco W. Schilham2, Erik G. J. von Asmuth2, Anja M. Jansen-Hoogendijk2, Cornelia M. Jol-van der Zijde2, Maarten J. D. van Tol2, Robbert G. M. Bredius3, Tayfun Güngör1, Arjan C. Lankester3, Dirk Jan A. R. Moes4
1Department of Pediatric Stem Cell Transplantation and Hematology, Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland
2Laboratory for Pediatric Immunology, Willem Alexander Children’s Hospital, Leiden University Medical Center, Leiden, The Netherlands
3Department of Pediatric Stem Cell Transplantation, Willem-Alexander Children’s Hospital, Leiden University Medical Center, Leiden, The Netherlands
4Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands

Tóm tắt

Abstract

Alemtuzumab (anti-CD52 antibody) is frequently prescribed to children with nonmalignant diseases undergoing allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft failure (GF) and acute graft-versus-host disease (aGVHD). The aim of this multicenter study was the characterization of alemtuzumab population pharmacokinetics to perform a novel model–based exposure-response analysis in 53 children with nonmalignant immunological or hematological disease and a median age of 4.4 years (interquartile range [IQR], 0.8-8.7). The median cumulative alemtuzumab dose was 0.6 mg/kg (IQR, 0.6-1) administered over 2 to 7 days. A 2-compartment population pharmacokinetics model with parallel linear and nonlinear elimination including allometrically scaled bodyweight (median, 17.50 kg; IQR, 8.76-33.00) and lymphocyte count at baseline (mean, 2.24 × 109/L; standard deviation ± 1.87) as significant pharmacokinetic predictors was developed using nonlinear mixed effects modeling. Based on the model–estimated median concentration at day of HSCT (0.77 μg/mL; IQR, 0.33-1.82), patients were grouped into a low- (≤0.77 μg/mL) or high- (>0.77 μg/mL) exposure groups. High alemtuzumab exposure at day of HSCT correlated with delayed CD4+ and CD8+ T-cell reconstitution (P value < .0001) and increased risk of GF (P value = .043). In contrast, alemtuzumab exposure did not significantly influence the incidence of aGVHD grade ≥2, mortality, chimerism at 1 year, viral reactivations, and autoimmunity at a median follow-up of 3.3 years (IQR, 2.5-8.0). In conclusion, this novel population pharmacokinetics model is suitable for individualized intravenous precision dosing to predict alemtuzumab exposure in pediatric allogeneic HSCT for nonmalignant diseases, aiming at the achievement of early T-cell reconstitution and prevention of GF in future prospective studies.


Tài liệu tham khảo

Waldmann, 2005, CAMPATH: from concept to clinic, Philos Trans R Soc Lond B Biol Sci, 360, 1707, 10.1098/rstb.2005.1702 Lankester, 2021, EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity, Bone Marrow Transplant, 56, 2052, 10.1038/s41409-021-01378-8 Guilcher, 2018, Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: a review, Pediatr Transplant, 22, e13142, 10.1111/petr.13142 Riechmann, 1988, Reshaping human antibodies for therapy, Nature, 332, 323, 10.1038/332323a0 Buggins, 2002, Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab, Blood, 100, 1715, 10.1182/blood.V100.5.1715.h81702001715_1715_1720 Hale, 2001, The CD52 antigen and development of the CAMPATH antibodies, Cytotherapy, 3, 137, 10.1080/146532401753174098 Clark, 1985, Interaction of rat monoclonal antibodies with human killer cells, Adv Exp Med Biol, 186, 797 Clark, 2012, Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients, Sci Transl Med, 4, 117ra117, 10.1126/scitranslmed.3003008 Dyer, 1990, Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies, Leuk Lymphoma, 2, 179, 10.3109/10428199009053522 Hale, 1983, Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement, Blood, 62, 873, 10.1182/blood.V62.4.873.873 Hu, 2009, Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model, Immunology, 128, 260, 10.1111/j.1365-2567.2009.03115.x Siders, 2010, Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models, Leuk Lymphoma, 51, 1293, 10.3109/10428191003777963 Wiendl, 2013, Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS, Nat Rev Neurol, 9, 125, 10.1038/nrneurol.2013.2 Hotta, 2016, CD52-negative NK cells are abundant in the liver and less susceptible to alemtuzumab treatment, PLoS One, 11, e0161618, 10.1371/journal.pone.0161618 Marsh, 2016, Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT, Blood, 127, 503, 10.1182/blood-2015-07-659672 Marsh, 2010, Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation, Blood, 116, 5824, 10.1182/blood-2010-04-282392 Chakrabarti, 2003, T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival, Br J Haematol, 121, 109, 10.1046/j.1365-2141.2003.04228.x Rebello, 2001, Pharmacokinetics of CAMPATH-1H in BMT patients, Cytotherapy, 3, 261, 10.1080/146532401317070899 Spyridonidis, 2011, Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia, Bone Marrow Transplant, 46, 1363, 10.1038/bmt.2010.308 Lane, 2014, Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies, Biol Blood Marrow Transplant, 20, 243, 10.1016/j.bbmt.2013.11.005 Admiraal, 2019, Population pharmacokinetics of alemtuzumab (Campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome, Clin Pharmacokinet, 58, 1609, 10.1007/s40262-019-00782-0 Dong, 2022, Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation, Br J Clin Pharmacol, 88, 248, 10.1111/bcp.14955 Achini-Gutzwiller, 2023, Development and validation of an efficient and highly sensitive ELISA for alemtuzumab quantification in human serum and plasma, Ther Drug Monit, 45, 79, 10.1097/FTD.0000000000001037 Jonsson, 1999, Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM, Comput Methods Programs Biomed, 58, 51, 10.1016/S0169-2607(98)00067-4 Lindbom, 2005, PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM, Comput Methods Programs Biomed, 79, 241, 10.1016/j.cmpb.2005.04.005 Bergstrand, 2011, Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models, AAPS J, 13, 143, 10.1208/s12248-011-9255-z Keizer, 2011, Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM, Comput Methods Programs Biomed, 101, 72, 10.1016/j.cmpb.2010.04.018 R Core Team . R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing. 2021. Accessed 5 June 2022. https://www.R-project.org/. RStudio Team, 2020 Willemsen, 2015, Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab, Biol Blood Marrow Transplant, 21, 473, 10.1016/j.bbmt.2014.11.674 Allen, 2018, Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies, Blood, 132, 1438, 10.1182/blood-2018-01-828277 Wang, 2012, Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies, J Clin Pharmacol, 52, 1601, 10.1177/0091270011422812 Filipovich, 2005, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report, Biol Blood Marrow Transplant, 11, 945, 10.1016/j.bbmt.2005.09.004 Hale, 2004, Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration, Blood, 104, 948, 10.1182/blood-2004-02-0593 Arnold, 2021, A prospective pilot study of a novel alemtuzumab target concentration intervention strategy, Bone Marrow Transplant, 56, 3029, 10.1038/s41409-021-01460-1 de Taeye, 2020, FcγR binding and ADCC activity of human IgG allotypes, Front Immunol, 11, 740, 10.3389/fimmu.2020.00740 Temming, 2019, Functional attributes of antibodies, effector cells, and target cells affecting NK cell-mediated antibody-dependent cellular cytotoxicity, J Immunol, 203, 3126, 10.4049/jimmunol.1900985 Admiraal, 2015, Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis, Lancet Haematol, 2, e194, 10.1016/S2352-3026(15)00045-9
Thông tin
Thông tin xuất bản

Blood Advances

Tập 7

4462-4474

Thông tin tác giả